Valuation : Monte Rosa Therapeutics, Inc.

Market Cap 1.18B 1.02B 956M 873M 1.63B 111B 1.64B 11.3B 4.38B 57.2B 4.43B 4.34B 184B P/E 2026 *
-8.52x
P/E 2027 * -7.3x
Enterprise Value 1.18B 1.02B 956M 873M 1.63B 111B 1.64B 11.3B 4.38B 57.2B 4.43B 4.34B 184B EV / Sales 2026 *
22x
EV / Sales 2027 * 20.7x
Free-Float
99.44%
Yield 2026 *
-
Yield 2027 * -
1 day-3.76%
1 week+3.44%
Current month-0.72%
1 month-11.34%
3 months-15.46%
6 months-22.90%
Current year-11.73%
1 week 13.12
Extreme 13.12
15
1 month 13.12
Extreme 13.12
16.26
Current year 13.12
Extreme 13.12
25.77
1 year 4.79
Extreme 4.79
25.77
3 years 2.44
Extreme 2.44
25.77
5 years 2.44
Extreme 2.44
45.56
10 years 2.44
Extreme 2.44
45.56
Manager TitleAgeSince
Chief Executive Officer 55 01/01/2020
Chief Tech/Sci/R&D Officer - 17/03/2026
Chief Operating Officer 54 01/03/2021
Director TitleAgeSince
Director/Board Member 55 01/01/2020
Director/Board Member 49 01/04/2020
Director/Board Member 57 01/06/2020
Date Insider Type Main position Quantity % Market Cap. Importance
16/7/26 Sell

Chief Executive Officer

-9,500 0.0112%
15/7/26 Exercice

Chief Operating Officer

13,053 0.0155%
6/7/26 Exercice

Chief Technology Officer

18,000 0.0213%
Change 5-day change 1-year change 3-year change Capi.($)
-3.76%+3.44%+180.16%+124.68% 1.18B
-2.54%-2.84%-1.77%+14.72% 48.93B
-0.40%+1.03%+418.57%+523.39% 45.01B
-1.42%+2.30%+42.67%+21.22% 44.07B
-1.22%-2.31%+4.82%+74.90% 40.73B
+0.53%-1.36%+16.87%+47.12% 33.52B
-0.21%+9.14% - - 17.77B
-0.35%-1.56%+21.42%+123.04% 16.5B
-1.01%+0.50%+13.91%+31.45% 14.67B
-1.65%-1.03%+75.93%+41.22% 13.77B
Average -1.20%+0.82%+85.84%+111.31% 27.62B
Weighted average by Cap. -1.04%+0.12%+89.83%+127.91%

Financials

2026 *2027 *
Net sales 53.67M 46.18M 43.45M 39.69M 74.25M 5.07B 74.46M 513M 199M 2.6B 202M 197M 8.38B 57.07M 49.11M 46.2M 42.21M 78.95M 5.39B 79.17M 546M 212M 2.76B 214M 210M 8.91B
Net income -164M -141M -133M -121M -227M -15.5B -228M -1.57B -610M -7.95B -617M -603M -25.62B -201M -173M -163M -149M -279M -19.01B -279M -1.93B -747M -9.75B -756M -739M -31.42B
Net Debt - -
Logo Monte Rosa Therapeutics, Inc.
Monte Rosa Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing a portfolio of novel and molecular glue degraders (MGDs). MGDs are small molecule drugs that employ the body’s natural protein destruction mechanisms to selectively degrade therapeutically relevant proteins. It has developed a proprietary and industry leading discovery engine, called Quantitative and Engineered Elimination of Neosubstrates (QuEEN) to enable its target centric MGD discovery and development approach and its rational design of MGD product candidates. Its product candidate, MRT-2359, is an orally bioavailable MGD targeting the translation termination factor protein GSPT1. MRT-2359 is in clinical development for potential use in MYC-driven tumors, including metastatic non-small cell lung cancer, small cell lung cancer, and neuroendocrine tumors. Its other product candidates include MRT-6160 and MRT-8102.
Employees
173
Date Price Change Volume
04/09/26 US$13.84 -3.76% 804,585
03/09/26 US$14.38 +1.13% 672,732
02/09/26 US$14.22 -0.63% 1,530,364
01/09/26 US$14.31 +2.65% 796,289
31/08/26 US$13.94 +4.19% 1,109,726
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
13.84USD
Average target price
28.50USD
Spread / Average Target
+105.92%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. GLUE Stock